These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 22659241)

  • 41. Role of interleukin-2 in patients with HIV infection.
    Pett SL; Kelleher AD; Emery S
    Drugs; 2010 Jun; 70(9):1115-30. PubMed ID: 20518579
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The role of latency reversal agents in the cure of HIV: A review of current data.
    Bashiri K; Rezaei N; Nasi M; Cossarizza A
    Immunol Lett; 2018 Apr; 196():135-139. PubMed ID: 29427743
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Modeling the timing of antilatency drug administration during HIV treatment.
    Petravic J; Martyushev A; Reece JC; Kent SJ; Davenport MP
    J Virol; 2014 Dec; 88(24):14050-6. PubMed ID: 25253352
    [TBL] [Abstract][Full Text] [Related]  

  • 44. HIV-Specific Granzyme B-Secreting but Not Gamma Interferon-Secreting T Cells Are Associated with Reduced Viral Reservoirs in Early HIV Infection.
    Yue FY; Cohen JC; Ho M; Rahman AKMN; Liu J; Mujib S; Saiyed A; Hundal S; Khozin A; Bonner P; Liu D; Benko E; Kovacs C; Ostrowski M
    J Virol; 2017 Apr; 91(8):. PubMed ID: 28179527
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Latently infected cell activation: a way to reduce the size of the HIV reservoir?
    Forde J; Volpe JM; Ciupe SM
    Bull Math Biol; 2012 Jul; 74(7):1651-72. PubMed ID: 22562387
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Therapeutic Approaches to Eradicate Latent HIV-1 in Resting CD4+ T Cells.
    Sluis-Cremer N
    Curr Top Med Chem; 2016; 16(10):1191-7. PubMed ID: 26324046
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Extracellular vesicle-mediated intercellular communication in HIV-1 infection and its role in the reservoir maintenance.
    Olivetta E; Chiozzini C; Arenaccio C; Manfredi F; Ferrantelli F; Federico M
    Cytokine Growth Factor Rev; 2020 Feb; 51():40-48. PubMed ID: 31926807
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Potential of Radiation-Induced Cellular Stress for Reactivation of Latent HIV-1 and Killing of Infected Cells.
    Iordanskiy S; Kashanchi F
    AIDS Res Hum Retroviruses; 2016 Feb; 32(2):120-4. PubMed ID: 26765533
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Maraviroc Is Associated with Latent HIV-1 Reactivation through NF-κB Activation in Resting CD4
    Madrid-Elena N; García-Bermejo ML; Serrano-Villar S; Díaz-de Santiago A; Sastre B; Gutiérrez C; Dronda F; Coronel Díaz M; Domínguez E; López-Huertas MR; Hernández-Novoa B; Moreno S
    J Virol; 2018 May; 92(9):. PubMed ID: 29444937
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Advancements in Developing Strategies for Sterilizing and Functional HIV Cures.
    Xu W; Li H; Wang Q; Hua C; Zhang H; Li W; Jiang S; Lu L
    Biomed Res Int; 2017; 2017():6096134. PubMed ID: 28529952
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Dual TLR2 and TLR7 agonists as HIV latency-reversing agents.
    Macedo AB; Novis CL; De Assis CM; Sorensen ES; Moszczynski P; Huang SH; Ren Y; Spivak AM; Jones RB; Planelles V; Bosque A
    JCI Insight; 2018 Oct; 3(19):. PubMed ID: 30282829
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Activation and lysis of human CD4 cells latently infected with HIV-1.
    Pegu A; Asokan M; Wu L; Wang K; Hataye J; Casazza JP; Guo X; Shi W; Georgiev I; Zhou T; Chen X; O'Dell S; Todd JP; Kwong PD; Rao SS; Yang ZY; Koup RA; Mascola JR; Nabel GJ
    Nat Commun; 2015 Oct; 6():8447. PubMed ID: 26485194
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Dynamics of the pool of infected resting CD4 HLA-DR- T lymphocytes in patients who started a triple class five-drug antiretroviral regimen during primary HIV-1 infection.
    Sankatsing SU; van Praag RM; van Rij RP; Rientsma R; Jurriaans S; Lange JM; Prins JM; Schuitemaker H
    Antivir Ther; 2003 Apr; 8(2):137-42. PubMed ID: 12741626
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Viral sanctuaries during highly active antiretroviral therapy in a nonhuman primate model for AIDS.
    North TW; Higgins J; Deere JD; Hayes TL; Villalobos A; Adamson L; Shacklett BL; Schinazi RF; Luciw PA
    J Virol; 2010 Mar; 84(6):2913-22. PubMed ID: 20032180
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [National consensus document by GESIDA/National Aids Plan on antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2011 update)].
    Panel de expertos de GESIDA y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2011 Mar; 29(3):209.e1-103. PubMed ID: 21388714
    [TBL] [Abstract][Full Text] [Related]  

  • 56. HIV infection: how effective is drug combination treatment?
    Grossman Z; Feinberg M; Kuznetsov V; Dimitrov D; Paul W
    Immunol Today; 1998 Nov; 19(11):528-32. PubMed ID: 9818549
    [TBL] [Abstract][Full Text] [Related]  

  • 57. High levels of CD2 expression identify HIV-1 latently infected resting memory CD4+ T cells in virally suppressed subjects.
    Iglesias-Ussel M; Vandergeeten C; Marchionni L; Chomont N; Romerio F
    J Virol; 2013 Aug; 87(16):9148-58. PubMed ID: 23760244
    [TBL] [Abstract][Full Text] [Related]  

  • 58. In Vitro Reactivation of Replication-Competent and Infectious HIV-1 by Histone Deacetylase Inhibitors.
    Banga R; Procopio FA; Cavassini M; Perreau M
    J Virol; 2016 Feb; 90(4):1858-71. PubMed ID: 26656693
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 60. What do we need to do to cure HIV infection.
    Siliciano RF
    Top HIV Med; 2010; 18(3):104-8. PubMed ID: 20921575
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.